Navigation Links
Algeta and Lumiphore Announce Global Agreement for the Development of Targeted Alpha-Pharmaceutical Therapeutics
Date:10/21/2010

RICHMOND, Calif., Oct. 21 /PRNewswire/ -- Lumiphore Inc., a biotechnology leader in new proprietary bifunctional metal-chelation technology for use in high-value imaging, diagnostics, and therapeutics and Algeta ASA (OSE:ALGETA), the cancer therapeutics company, announced that they have signed a global agreement on incorporation of Lumiphore's Lumi4® complexes in Algeta's targeted radiotherapeutics and companion diagnostics.

Under the agreement, Algeta has an option to the exclusive rights to incorporate Lumi4® isophthalamide chelation technology into future targeted radiopharmaceutical therapeutics for cancer.

"Lumiphore's goal is to bring the benefits of bifunctional metal-chelation technology to therapeutic markets that use targeted radiopharmaceuticals to treat cancer. The ability to chelate radioactive metal isotopes and covalently attach them to therapeutic antibodies, peptides, proteins, or other receptor targeting molecules will benefit targeted delivery to cancer sites and has the potential to make current therapeutic antibodies more effective," said Dr. Ken Raymond, President and CEO of Lumiphore.

Algeta has proprietary technology relating to the use of the alpha emitter thorium-227 to protein/peptides to target specific cancer cells. Thorium-227 is an isotope that emits high-energy alpha particles. Such isotopes are of considerable interest in the treatment of cancer as they are potent at killing tumor cells but have a highly localized effect. By linking thorium-227 to tumor-targeting molecules such as monoclonal antibodies, Algeta has the potential to create a pipeline of new generation alpha-pharmaceuticals designed to specifically seek and destroy cancers while minimizing damage to surrounding healthy tissues. "Using Lumi4® bifunctional chelates," explained Thomas Ramdahl, Chief Technology Officer of Algeta, "could create a new class of radioimmunotherapeutics. By linking thorium-227 to selected tumor targeting an
'/>"/>

SOURCE Lumiphore, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer
2. Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin
3. Boston Scientific Announces FDA Clearance and CE Mark Approval for Advanix™ Biliary Stents
4. Celtic Pharma Announces Issuance of U.S. Patent 7,816,323 for Xerecept® in Combination with Avastin® as a Treatment for Breast and Colon Cancers
5. Hanger Orthopedic Group, Inc. Announces Pricing of $200 Million of Senior Notes
6. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter and Nine-Months Ended September 30, 2010 and Declares Quarterly Dividend
7. K-V Pharmaceutical Company Announces Establishment of New Generic Marketing Subsidiary and Senior Executive Appointment
8. Endo Pharmaceuticals to Announce Third Quarter 2010 Financial Results on November 1, 2010
9. MacroGenics and Lilly Announce Pivotal Clinical Trial of Teplizumab Did Not Meet Primary Efficacy Endpoint
10. Amgen Announces Webcast of 2010 Third Quarter Financial Results
11. ERT to Announce Third Quarter 2010 Results on November 4, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 2014   Easy Breathe , the fastest growing online ... Blog " - has received more than 4.5 million unique page ... are thrilled that so many people are finding our blog and ... Breathe. "We,re committed to making sleep apnea more widely known and ... about sleep apnea news , troubleshooting advice , and ...
(Date:8/20/2014)... YORK, Aug 20, 2014 Reportlinker.com announces ... in its catalogue: Global Patient Scales ... This report analyzes the worldwide markets for ... Product Segments: Floor Scales, Infant & Baby Scales, ... provides separate comprehensive analytics for the US, Canada, ...
(Date:8/20/2014)... SAN MARCOS, Texas , Aug. 20, 2014 ... purchase of five diverse sets of patent families ... and major innovation driver for Bayer AG of ... The patents acquired provide broad intellectual property ... achieved in economical high-volume quantum dot (QD) manufacturing. ...
Breaking Medicine Technology:Easy Breathe Blog Emerges as the Go-To Resource for Sleep Apnea Sufferers 2Easy Breathe Blog Emerges as the Go-To Resource for Sleep Apnea Sufferers 3Easy Breathe Blog Emerges as the Go-To Resource for Sleep Apnea Sufferers 4Global Patient Scales Industry 2Global Patient Scales Industry 3Global Patient Scales Industry 4Global Patient Scales Industry 5Global Patient Scales Industry 6Global Patient Scales Industry 7Global Patient Scales Industry 8Global Patient Scales Industry 9Global Patient Scales Industry 10Global Patient Scales Industry 11Global Patient Scales Industry 12Global Patient Scales Industry 13Global Patient Scales Industry 14Global Patient Scales Industry 15Global Patient Scales Industry 16Global Patient Scales Industry 17Global Patient Scales Industry 18Global Patient Scales Industry 19Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 2Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 3Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 4
... Inc. (OTC Bulletin Board: SCLR ) today ... and Drug Administration (FDA) identifying deficiencies regarding its Abbreviated ... The Company said the letter identified a number ... of the bioequivalence study submitted by SCOLR to support ...
... DIEGO, March 11, 2011 Conatus Pharmaceuticals Inc. today announced ... trial data of CTS-1027 for the treatment of hepatitis C ... Association for the Study of the Liver (EASL) to be ... 2011. Specifically, abstract 562 entitled: 24-WEEK TREATMENT WITH ...
Cached Medicine Technology:SCOLR Pharma, Inc. Receives Deficiency Letter from FDA on Pseudoephedrine Application 2Conatus Pharmaceuticals Will Display HCV Clinical Trial Data at the International Liver Congress™ (EASL) in March 2
(Date:8/21/2014)... August 21, 2014 While golfing in ... it hard to stay focused on his game due ... The constant whine, slapping and continual need to spray ... methods to stay protected from insects while golfing. He ... in the Financial Services/Investment Banking Industry, decided to change ...
(Date:8/21/2014)... Atlantic Information Services, Inc. (AIS) — industry-leading ... The AIS Report on Blue Cross & Blue Shield ... Association or its member companies) — is pleased to ... Management Insight Series. Bundled Payment Models: Bottom-Line Strategies ... — Horizon Healthcare Services, Inc. and Arkansas Blue Cross ...
(Date:8/21/2014)... San Diego, CA (PRWEB) August 21, 2014 ... website daily regarding all the latest information from the ... Solution . , The US FDA announced on August ... Peritoneal Dialysis Solution with 2.5% Dextrose 5000mL (Ambu-Flex II), ... to the presence of particulate matter. , The ...
(Date:8/21/2014)... Sometimes you have to lose the life of your dreams ... to a Hundred: Finding My Purpose through My Pain,” Jason Roy, ... broken family, a childhood of gang violence and two life-altering car ... to be,” Roy said. “I didn’t give up on God when ... today of helping others overcome their trials.” , He said his ...
(Date:8/21/2014)... August 21, 2014 OpsAssure, the ... start-ups selected to participate in the Harbor Accelerator's ... mentorship, curriculum sessions and valuable resources.he Harbor’s goal ... the region. Each start-up selected for the program ... order to help businesses grow quickly, test markets ...
Breaking Medicine News(10 mins):Health News:Financial VP Fights Pesky Bugs with Launch of Biteback Sports Insect Shield® Golf Apparel 2Health News:New AIS Report Highlights Two Case Studies of Bundled Payment Models 2Health News:Dianeal Low Calcium (2.5mEq/L) Peritoneal Dialysis Solution with 2.5% Dextrose 5000mL (Ambu-Flex II) Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Zero to a Hundred: True Story of Escaping Death to Meet Life 2
... , , OAKLAND, Calif. , Jan. 13 ... have responded in less than one day to the call by ... assistance to residents of earthquake devastated Haiti —leading the ... support these efforts with donations of funds to support travel costs ...
... ... ... 2010 -- Connextions Inc. today announced the appointment of Kenneth A. Burdick ... with an outstanding record of management and fiscal performance with the nation’s most respected ...
... , KIRKLAND, Wash. , Jan. 13 Long term ... Lifetime Television,s Balancing Act show. Denise Gott , the featured expert, ... term care for our loved ones. "Three in four will eventually need ... (LTCFP), one of America,s most experienced long term care insurance ...
... , ... the trusted leader in acne treatment for 15 years, today ... revolutionized the treatment of acne now enhanced with exclusive micro-crystal ... to penetrate even clogged pores quickly is the first change ...
... surgeons say , WEDNESDAY, Jan. 13 (HealthDay News) -- ... coaxed a donor trachea to grow its own network ... for months in the recipient,s arm. , The innovative ... trachea (windpipe), but it did so without the need ...
... treatment, researcher says, , WEDNESDAY, Jan. 13 (HealthDay News) -- ... turn cancerous. , At issue is how mutations occur in ... Jan. 13 in Nature , researchers report that cancer-causing ... , "The bad news is that it is much easier ...
Cached Medicine News:Health News:National Conference Call Thursday for 1,500 RN Volunteers for Haiti Relief Effort 2Health News:Veteran Health Insurance Senior Executive Joins Connextions Inc. Board of Directors 2Health News:Veteran Health Insurance Senior Executive Joins Connextions Inc. Board of Directors 3Health News:Long Term Care Insurance Expert Featured on Lifetime Television's Balancing Act Show 2Health News:Proactiv(R) Introduces New Micro-Crystal Technology and Unprecedented Customer Access to Expert Acne Treatment Advice 2Health News:Proactiv(R) Introduces New Micro-Crystal Technology and Unprecedented Customer Access to Expert Acne Treatment Advice 3Health News:Proactiv(R) Introduces New Micro-Crystal Technology and Unprecedented Customer Access to Expert Acne Treatment Advice 4Health News:Proactiv(R) Introduces New Micro-Crystal Technology and Unprecedented Customer Access to Expert Acne Treatment Advice 5Health News:Transplanted Trachea Grows Own Blood Supply in Patient's Arm 2Health News:Transplanted Trachea Grows Own Blood Supply in Patient's Arm 3
Angled 45 degree shafts 8 mm long with 1 x 2 teeth and 5 mm tying platform. Serrated handle with dull finish....
Heavy curved shafts with 2 x 2 teeth and crisscross serrated 6 mm tying platform. Serrated handle with polished finish....
Straight shafts with teeth and 6 mm crisscross serrated tying surfaces. Serrated handle with polished finish....
Straight shafts with 1 x 2 teeth and serrated handle with polished finish....
Medicine Products: